BioCentriq, a Newark, NJ-based cell-based therapy contract development and manufacturing organization (CDMO), raised $29.2M in Series A funding.
The backers were not disclosed.
The company intends to use the funds to enhance its facilities, invest in advanced technologies, and expand its team.
Led by CEO James Park, BioCentriq specializes in cell therapy contract development and manufacturing, with a track record transferring, developing, and manufacturing GMP drug product for use in clinical trials. The company’s comprehensive suite of services includes process development, manufacturing, and analytical testing ensuring seamless and efficient development of cell-based therapies for diverse therapeutic areas.
FinSMEs
03/01/2024